Mining News
ZEN Graphene shares soar on breakthrough in graphene-based treatment of viral infections
 |
| Image credit: Golden Minerals. |
(Kitco News) - ZEN Graphene Solutions (TSXV:ZEN, OTC:ZENYF) announced today that it has developed a potential graphene-based antibiotic, antiviral and antifungal compound.
According to the company’s statement, recently received testing results from the University Health Network/Mount Sinai Hospital Department of Microbiology in Toronto indicate that this patent pending formulation could be a “medical breakthrough in the treatment of numerous human-contracted pathogens including, upper and lower respiratory tract infections – where COVID-19 is a major contributor – as well as drug resistant organisms.”
Testing was conducted by Dr. Tony Mazzulli, MD, FRCPC, FACP, Microbiologist-in-Chief & Infectious Disease Specialist at Mount Sinai Hospital.
CEO Greg Fenton commented, “This broad-spectrum compound is a novel solution that could have an impact on infectious disease management. It has the potential to act as a targeted treatment for multi-drug resistant organisms as well. As in previously released results on the effectiveness of a similar compound against COVID-19, this graphene-based treatment could be against viral infections. We will be exploring its use not only in the fight against the current global pandemic, but also against numerous other pathogens.”
ZEN is a graphene technology solutions company with a focus on the development of graphene-based nanomaterial products and applications. The company’s Albany graphite project has a potential competitive advantage in the graphene market as independent labs in Japan, UK, Israel, USA and Canada have independently demonstrated that ZEN’s Albany PureTM Graphite is an ideal precursor material which easily converts (exfoliates) to graphene, using a variety of mechanical, chemical and electrochemical methods. ZEN is focused on commercializing a patent pending graphene-based coating with 99% viricidal activity against COVID-19.
